Instylla Initiates Commercial Launch with First Use of the Embrace™ Hydrogel Embolic System
Milestone marks the commercial use of the first and only liquid embolic approved for hypervascular tumor embolization supported by a prospective, randomized, controlled clinical trial BEDFORD, Mass., January 28th, 2026 – Instylla, Inc., a privately held company developing novel resorbable embolics for peripheral vascular embolization, today announced that Dr. Ripal Gandhi has completed the first […]